Compare PAX & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PAX | MPLT |
|---|---|---|
| Founded | 1988 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2020 | 2025 |
| Metric | PAX | MPLT |
|---|---|---|
| Price | $11.49 | $7.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 15 |
| Target Price | $15.00 | ★ $26.54 |
| AVG Volume (30 Days) | ★ 1.1M | 420.3K |
| Earning Date | 11-03-2026 | 12-03-2026 |
| Dividend Yield | ★ 5.59% | N/A |
| EPS Growth | N/A | ★ 82.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.76 | N/A |
| Revenue Next Year | $10.10 | N/A |
| P/E Ratio | $25.65 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.89 | $7.85 |
| 52 Week High | $17.80 | $40.43 |
| Indicator | PAX | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 61.63 | 22.05 |
| Support Level | $11.04 | N/A |
| Resistance Level | $11.62 | $20.46 |
| Average True Range (ATR) | 0.28 | 0.58 |
| MACD | 0.17 | -0.04 |
| Stochastic Oscillator | 79.80 | 11.14 |
Patria Investments Ltd is an alternative asset management firm specializing in resilient sectors across select regions. It seeks to provide world-wide and Latin American investors with attractive investment products that allows portfolio diversification and consistent returns. The group promotes inclusive and sustainable development in the Asset Classes: Private Equity, Private Equity Solutions, Credit, Real Estate, Infrastructure, and Public Equities Main sectors: Agribusiness, Power & Energy, Healthcare, Logistics & Transportations, Food & Beverage and Digital & Tech Services Investment Regions.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.